Establishment Labs (NASDAQ:ESTA) Price Target Raised to $95.00 at JPMorgan Chase & Co.

Establishment Labs (NASDAQ:ESTA) had its price objective hoisted by JPMorgan Chase & Co. from $84.00 to $95.00 in a research note released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other research analysts also recently issued research reports about the stock. Citigroup increased their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a research report on Thursday. BTIG Research raised their price objective on Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Needham & Company LLC lifted their target price on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $100.25.

Establishment Labs Trading Down 2.1%

ESTA stock opened at $77.42 on Friday. The firm has a fifty day moving average price of $86.43 and a 200 day moving average price of $74.25. Establishment Labs has a fifty-two week low of $33.35 and a fifty-two week high of $97.59. The firm has a market cap of $2.28 billion, a PE ratio of -59.10 and a beta of 1.07. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 205.79%. The business had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. During the same period in the previous year, the company earned ($0.57) EPS. Establishment Labs’s revenue for the quarter was up 31.7% compared to the same quarter last year. Sell-side analysts anticipate that Establishment Labs will post -1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ESTA. Simplify Asset Management Inc. boosted its holdings in Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock valued at $5,313,000 after acquiring an additional 34,946 shares during the period. Sigma Planning Corp increased its stake in Establishment Labs by 325.5% in the first quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock worth $1,160,000 after purchasing an additional 15,624 shares during the period. SG Americas Securities LLC increased its stake in Establishment Labs by 134.3% in the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock worth $2,154,000 after purchasing an additional 21,742 shares during the period. AlTi Global Inc. purchased a new stake in Establishment Labs in the first quarter worth $842,000. Finally, Union Square Park Capital Management LLC lifted its position in shares of Establishment Labs by 16.7% during the first quarter. Union Square Park Capital Management LLC now owns 105,000 shares of the company’s stock worth $5,962,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Key Establishment Labs News

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Establishment Labs from $84 to $95 and maintained an Overweight rating, implying substantial upside from the current trading level. Benzinga analyst report
• Positive Sentiment: BTIG increased its price target from $96 to $103 and reiterated a Buy rating, while Needham lifted its target from $86 to $95 and also maintained a Buy rating. These revisions suggest analysts remain optimistic about the company’s growth prospects. The Fly analyst report
• Positive Sentiment: Establishment Labs reported quarterly revenue of $67.54 million, exceeding the $65.79 million analyst estimate and increasing 31.7% year over year. The company also projected 2026 revenue of $269 million to $271 million, above the $267.5 million consensus estimate. Zacks quarterly results report
• Neutral Sentiment: Management indicated that minimally invasive procedures now account for approximately 15% of sales, highlighting potential for longer-term market expansion, but investors may remain focused on the company’s path to profitability. Seeking Alpha revenue outlook report
• Negative Sentiment: The company reported a second-quarter loss of $0.39 per share, wider than the $0.34 expected loss, though the result improved from a $0.57 loss in the year-ago quarter. The earnings miss, continued negative margins, and lack of profitability are likely weighing on the shares. MarketBeat earnings report

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.